143 related articles for article (PubMed ID: 22982218)
1. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
Lavarone E; Puppin C; Passon N; Filetti S; Russo D; Damante G
Mol Cell Endocrinol; 2013 Jan; 365(1):1-10. PubMed ID: 22982218
[TBL] [Abstract][Full Text] [Related]
2. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
[TBL] [Abstract][Full Text] [Related]
3. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.
Puppin C; D'Aurizio F; D'Elia AV; Cesaratto L; Tell G; Russo D; Filetti S; Ferretti E; Tosi E; Mattei T; Pianta A; Pellizzari L; Damante G
Endocrinology; 2005 Sep; 146(9):3967-74. PubMed ID: 15919754
[TBL] [Abstract][Full Text] [Related]
4. Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells.
Li W; Ain KB
Endocr Relat Cancer; 2010 Jun; 17(2):383-98. PubMed ID: 20228127
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.
Wang Z; Li Y; Lv S; Tian Y
J Int Med Res; 2013 Oct; 41(5):1577-85. PubMed ID: 24097829
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Baldan F; Mio C; Lavarone E; Di Loreto C; Puglisi F; Damante G; Puppin C
Oncol Rep; 2015 May; 33(5):2199-206. PubMed ID: 25812606
[TBL] [Abstract][Full Text] [Related]
7. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
[TBL] [Abstract][Full Text] [Related]
8. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line.
Choi HJ; Kim TY; Ruiz-Llorente S; Jeon MJ; Han JM; Kim WG; Shong YK; Kim WB
Nucl Med Biol; 2012 Nov; 39(8):1275-80. PubMed ID: 22995901
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.
Smith VE; Sharma N; Watkins RJ; Read ML; Ryan GA; Kwan PP; Martin A; Watkinson JC; Boelaert K; Franklyn JA; McCabe CJ
J Clin Endocrinol Metab; 2013 Jul; 98(7):2876-86. PubMed ID: 23678037
[TBL] [Abstract][Full Text] [Related]
10. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
[TBL] [Abstract][Full Text] [Related]
11. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
Wächter S; Wunderlich A; Greene BH; Roth S; Elxnat M; Fellinger SA; Verburg FA; Luster M; Bartsch DK; Di Fazio P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018229
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells.
Passon N; Puppin C; Lavarone E; Bregant E; Franzoni A; Hershman JM; Fenton MS; D'Agostino M; Durante C; Russo D; Filetti S; Damante G
Thyroid; 2012 May; 22(5):487-93. PubMed ID: 22510021
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
Jasek E; Gajda M; Lis GJ; Jasińska M; Litwin JA
Anticancer Res; 2014 Apr; 34(4):1849-56. PubMed ID: 24692719
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
[TBL] [Abstract][Full Text] [Related]
15. Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression.
Gao A; Zuo X; Liu Q; Lu X; Guo W; Tian L
Toxicol Lett; 2010 Jun; 195(2-3):114-8. PubMed ID: 20230882
[TBL] [Abstract][Full Text] [Related]
16. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC).
Provenzano MJ; Fitzgerald MP; Krager K; Domann FE
Otolaryngol Head Neck Surg; 2007 Nov; 137(5):722-8. PubMed ID: 17967635
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines.
Gangopadhyay NN; Luketich JD; Opest A; Visus C; Meyer EM; Landreneau R; Schuchert MJ
Cancer Invest; 2011 Nov; 29(9):608-16. PubMed ID: 22011283
[TBL] [Abstract][Full Text] [Related]
18. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation.
Pang J; Cui J; Xi C; Shen T; Gong H; Dou L; Lin Y; Zhang T
Cell Physiol Biochem; 2018; 49(2):645-652. PubMed ID: 30165350
[TBL] [Abstract][Full Text] [Related]
20. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
